Aislinn Antrim, Associate Editorial Director

pCR rates were improved with the addition of pembrolizumab regardless of whether patients received the full chemotherapy doses.

MONARCH 3 final OS data show that the combination of abemaciclib and a NSAI in the first-line resulted in numerically longer OS compared to an NSAI alone.

Patients with an estrogen receptor measure greater than 8% and those with little to no TIL expression showed no benefit with the addition of nivolumab.

The investigational combination also delayed the median time to first chemotherapy in all age groups.

Biologic rationale, biomarker precision, and efficacy results in the biomarker-negative population all helped FDA officials decide the final indication.

Evidence has shown that reversing pro-cancer effects requires significant weight loss as well as substantial metabolic reprogramming.

Trastuzumab deruxtecan and elacestrant both represent important new treatment options for subgroups of patients with breast cancer.

The designation allows expedited development of ADP101 as a treatment for food allergy in children ages 4 to 17 with confirmed allergy to 1 or more of the 15 foods in the drug product.

Tirzepatide is already approved under the brand name Mounjaro (Lilly) to be used along with diet and exercise to improve blood sugar in adults with type 2 diabetes.

The approval marks the first new biologic treatment option for this patient population in nearly a decade.

Risk of long COVID was 3 times higher in those who had pre-existing conditions and a short sleep duration, compared to those with no pre-existing conditions and adequate sleep.

The approval marks the first and only once-daily target therapy for generalized myasthenia gravis for self-administration in this patient population.

If health care professionals want to increase access and care in these underrepresented communities, an important first step is also increasing the representation of those groups in health care itself.

The intravenous formulation of secukinumab is administered in monthly 30-minute, weight-based dosing and requires no pre-medication or lab monitoring.

Choice of therapy should be selected based on patient needs and conditions.

Although respondents reported no impacts on patient safety, workload significantly increased during the COVID-19 pandemic and led to major burnout challenges.

Axicabtagene ciloleucel achieved a complete metabolic response of 71% at 3 months versus 12% expected with standard of care among transplant ineligible patients with relapsed/refractory large B-cell lymphoma.

A supplemental New Drug Application will be submitted for roflumilast cream 0.05% for the treatment of mild to moderate atopic dermatitis in children 2 to 5 years of age.

Shared decision-making can be better incorporated into cardiovascular care guidelines by including decision aids, such as informational flyers or online tools to help patients.

Bispecific antibodies have 2 distinct binding domains, which interact with either CD3 on T cells or a tumor-associated antigen on the tumor cell surface.

As a once-daily oral treatment, orforglipron could help address barriers to injectable medications, such as semaglutide and liraglutide.

The use of base editing to generate universal, off-the-shelf CAR T cells is a promising approach for relapsed leukemia, with potential implications for the future of gene therapy.

Bispecific antibodies have offered a new treatment approach in relapsed/refractory multiple myeloma, with promising results in preclinical studies for multiple cancers and hematological malignancies.

Telemedicine approaches for HIV can help reduce stigma that is often a challenge in face-to-face clinical settings and eliminate common logistical barriers, such as transportation.

One IVIG product showed overall improvement in neuroprotection, including alleviating cognitive decline and ameliorating AB deposition in Alzheimer disease.

Hypercortisolemia during the late afternoon and early evening is harmful and believed to cause insulin resistance observed with advanced age.

With pharmacies around the country shifting to provide more comprehensive care and becoming true health care destinations, Chichi Ilonzo Momah, PharmD, RPh said she is excited for the future of the field.

In addition to improving risk evaluation in older adults at home, point-of-care testing may help clinicians manage patients with dementia who cannot communicate and those living in depopulated areas.

Correctly diagnosing specific follicular lymphomas and marginal zone lymphomas requires knowledge of the clinical context, including the site of involvement, age, and clinical presentation.

In a previous trial, DARE-19, investigators reported that the SGLT2 inhibitor dapagliflozin did not benefit patients with COVID-19 who had cardiometabolic risk factors.